Business Description
ISIN : US2197981051
Share Class Description:
QDEL: Ordinary SharesTotal Employee Number:
6,500Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.04 | |||||
Equity-to-Asset | 0.31 | |||||
Debt-to-Equity | 1.73 | |||||
Debt-to-EBITDA | -8.12 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.07 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10.9 | |||||
3-Year EPS without NRI Growth Rate | -47.8 | |||||
3-Year Book Growth Rate | -27.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.33 | |||||
9-Day RSI | 47.65 | |||||
14-Day RSI | 47.25 | |||||
3-1 Month Momentum % | 27.54 | |||||
6-1 Month Momentum % | -26.69 | |||||
12-1 Month Momentum % | -40.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.39 | |||||
Quick Ratio | 0.76 | |||||
Cash Ratio | 0.12 | |||||
Days Inventory | 147.85 | |||||
Days Sales Outstanding | 48.87 | |||||
Days Payable | 58.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | -17.92 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 44.6 | |||||
Operating Margin % | -1.3 | |||||
Net Margin % | -39.2 | |||||
EBITDA Margin % | -14.17 | |||||
FCF Margin % | -7.9 | |||||
OCF Margin % | -2.14 | |||||
ROE % | -50.52 | |||||
ROA % | -17.97 | |||||
ROIC % | -0.66 | |||||
3-Year ROIIC % | 23.17 | |||||
ROC (Joel Greenblatt) % | -42.7 | |||||
ROCE % | -17.12 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 19.07 | |||||
PE Ratio without NRI | 10.92 | |||||
Shiller PE Ratio | 14.46 | |||||
PS Ratio | 0.38 | |||||
PB Ratio | 0.57 | |||||
EV-to-EBIT | -4.76 | |||||
EV-to-Forward-EBIT | 9 | |||||
EV-to-EBITDA | -10.46 | |||||
EV-to-Forward-EBITDA | 5.95 | |||||
EV-to-Revenue | 1.48 | |||||
EV-to-Forward-Revenue | 1.43 | |||||
EV-to-FCF | -18.76 | |||||
Price-to-GF-Value | 0.44 | |||||
Price-to-Projected-FCF | 0.28 | |||||
Price-to-Median-PS-Value | 0.12 | |||||
Earnings Yield (Greenblatt) % | -21.01 | |||||
FCF Yield % | -20.89 | |||||
Forward Rate of Return (Yacktman) % | 78.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QDEL
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
QuidelOrtho Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,674.2 | ||
| EPS (TTM) ($) | -15.41 | ||
| Beta | 0.6714 | ||
| 3-Year Sharpe Ratio | -0.84 | ||
| 3-Year Sortino Ratio | -1 | ||
| Volatility % | 63 | ||
| 14-Day RSI | 47.25 | ||
| 14-Day ATR ($) | 1.107315 | ||
| 20-Day SMA ($) | 14.9615 | ||
| 12-1 Month Momentum % | -40.46 | ||
| 52-Week Range ($) | 9.92 - 35.575 | ||
| Shares Outstanding (Mil) | 68.58 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
QuidelOrtho Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
QuidelOrtho Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-19 | In 173 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-11 17:00 | In 166 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-11 | In 165 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 17:00 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 67 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 17:00 | 17.50 (+0.66%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 17.50 (+0.66%) | ||
| General meeting for 2026 | 2026-06-16 08:30 | 14.57 (+0.48%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 08:10 | 13.29 (+2.63%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-02 12:20 | 13.27 (+4.00%) |
QuidelOrtho Corp Frequently Asked Questions
Guru Commentaries on NAS:QDEL
I believe QDEL is a once-in-five-to-ten-year opportunity, and I plan to retain a significant investment for the foreseeable future. QDEL is essentially three different businesses operating under one corporate entity, and a division could be sold to deleverage the company. According to the FT article, QDEL is looking to sell its POC division for roughly $1.5B. Assuming a sale near the rumored price, the QDEL RemainCo would be ~2.5x levered and consist of the legacy Ortho business. Once the Chinese regulations are finalized in the coming months, I believe the legacy Ortho business will return to its historical, consistent high single-digit EBITDA growth.
QuidelOrtho Corp. is a global leader in the medical diagnostics industry. We invested in the third quarter of 2022 following pandemic-related earnings pressure. Our thesis was that Quidel’s 2022 merger with Ortho Clinical Diagnostics positioned the company as a top-tier diagnostics platform with the potential for improved top-line growth, margins, and free cash flow. While the company’s earnings report during the most recent quarter was in line with expectations and guidance was unchanged, the stock struggled due to broader macro concerns. Despite near-term headwinds, we see evidence of business improvements taking place under new leadership, and we maintained our position during the quarter.
Press Release
Articles on QuidelOrtho Corp
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
